Progress in the development of an HIV vaccine

Bibliography

• SEPKOWITZ KA: AIDS - the first 20 years. N Engl.J. Med. (2001) 344:1764–1782.
   PubMed Web of Science ®Google Scholar
• GAYLE HD, HILL GL: Global impact of human immunodeficiency virus and AIDS. Clin. Microbiol Rev (2001) 14:327–335.
   PubMed Web of Science ®Google Scholar
• COMBADIERE B, CARCELAIN G, DEBRE P et al.: Plasticity of lymphoid compartments during HIV infection and treatments: hopes and limits. Microb. Infect. (2002) 4:575–580.
   PubMed Web of Science ®Google Scholar
• TRAMONT EC: Treponema pallid-Syphilis. In: Principles and practice of infectious diseases (5th edition). Mandell GL, Bennett JE, Dolin R (Eds) John Wiley and Son, New York (2000).
   Google Scholar
• CELENTANO DD, BOND KC, LYLES CM et al.: Prevention intervention to reduce sexually transmitted infection: a field trial in the Royal Thai Army. Arch. Intern. Med. (2000) 160:535–540.
   PubMed Web of Science ®Google Scholar
• CHUN TW, FAUCI AS: Latent reservoirs of HIV: obstacles to the eradication of virus. Proc. Nail Acad. Sci. USA (1999) 96:10958–10961.
   PubMed Web of Science ®Google Scholar
• ALBERT MR, OSTHEIMER KG, LIE WEHR DJ et al.: Smallpox manifestations and survival during the Boston epidemic of 1901-1903. Ann. Intern. Med. (2002) 137:993–1000.
   PubMed Web of Science ®Google Scholar
• ROBINSON WS: Hepatitis B virus and Hepatitis D virus. In: Principles and practice of infectious diseases. Mandell GL, Bennett JE, Dolin R (Eds) Churchill Livingstone, New York (2000).
   Google Scholar
• LYLES RH, MUNOZ A, YAMASHITA TE et al.: Natural history of human imunnodeficiency virus type I viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men.' Infect. Dis. (2000) 181:872–880
   Google Scholar
• LOTTI B, WENDLAND T, FURRER H et al: Cytotoxic HIV-1 p55(gag)-specific CD4+ T cells produce HIV-inhibitory cytokines and chemokines. Clin. Immunol (2002) 22:253–262.
   Web of Science ®Google Scholar
• LETVIN NL: Stategies for an HIV vaccine. Clin. Invest. (2002) 110:15–20.
   Google Scholar
• LET VIN NL, BAROUCH DH, MONTEFIORI DC: Prospects for vaccine protection against HIV-1 infection and AIDS Ann. Rev Immunol (2002) 20:73–99.
   Google Scholar
• MASCOLA JR, NABEL GJ: Vaccines for the prevention of HIV-1 disease. Curt: Opin. Immunol (2001) 13:489–495.
   PubMed Web of Science ®Google Scholar
• ZHANG L, YU W, HE T et al.: Contribution of human a-defensin 1, 2, and 3 to the anti-HIV-1 activity of CB8 antiviral factor. Science. (2002) 298:995–1000.
   PubMed Web of Science ®Google Scholar
• PANTALEO G, DEMAREST JF, SCHACKER T et al.: The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc. Nati Acad. Sci. (1997) 94:254–258.
   PubMed Web of Science ®Google Scholar
• ADA GL: Vaccines and vaccination. N Engl. Med. (2001) 345:1042–1053.
   PubMed Web of Science ®Google Scholar
• ZHU T, MO H, WANG N et al.: Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science (1993) 261:1179–1181.
   PubMed Web of Science ®Google Scholar
• MASTRO TD, KITAYAPORN D: HIV type 1 transmission probabilities: estimates from epidemiological studies. AIDS Res. Hum. Retrovimses (1998) 14\(Suppl. 3):S223–S227.
   PubMedGoogle Scholar
• COHN MA, FRANKEL SS, RUGPASA S et al.: Chronic inflammation with increased human immunodeficiency virus expression in vaginal epithelium of HIV-infected Thai women. J. Infect. Dis. (2001) 184:410–417.
   PubMed Web of Science ®Google Scholar
• RISBAD A, CHAN-TACK K, GADKARI D et al.: The etiology of genital ulcer disease by multiplex polymerase chain reaction and relationship to HIV infection among patients attending a sexually transmitted disease clinic in Pune, India. S. Transm. Dis (1999) 26:55–62.
   PubMed Web of Science ®Google Scholar
• BEYRER C, ARTENSTEIN AW, RUGPAO S et al.: Epidemiologic and biologic characterization of a cohort of HIV highly exposed, persistently negative female sex workers in northern Thailand. I Infect. Dis. (1999) 179:59–67.
   Google Scholar
• FOWKE KR, NEGELKERKE NJ, KIMANI J et al.: Resistance to HIV-1 infection among persistently sero-negative prostitutes in Nairobi, Kenya. Lancet (1996) 348:1347–1351.
   PubMed Web of Science ®Google Scholar
• AMARA RR, VILLINGER F, ALTMAN JD et al.: Control of mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science (2001) 292:69–74.
   PubMed Web of Science ®Google Scholar
• BAROUCH DH, SANTRA S, SCHNITZ JE et al.: Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science (2000) 290:486–492.
   PubMed Web of Science ®Google Scholar
• MOSCOLA J, SYNDER SW, WEISLOW OS et al: Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type-1.I Infect. Dis. (1996) 173:340–348.
   PubMed Web of Science ®Google Scholar
• FERRANTELLI F, RASMUSSON RA, HOFMANN-LEHMANN R et al.: Do not underestimate the power of antibodies - lessons of antibody adoptive transfer. Vaccine (2002) 20\(Suppl. 4):A61–A64.
   Google Scholar
• DOUEK DC, BRENCHLEY JM, BETTS MR et al.: HIV preferentially infects HIV-specific CD4+T cells. Nature (2002) 417:95–98.
   PubMed Web of Science ®Google Scholar
• ARORA VK, FREDERICKSON BL, GARCIA JV: Nef: agent of cell subversion. Microb. Infect (2002) 4:189–199.
   PubMed Web of Science ®Google Scholar
• STEVENSON M: Tat's seductive side. Nat. Med. (2003) 9:163–164.
   PubMed Web of Science ®Google Scholar
• RICHMAN DD, T WINN, S LITTLE et al.: Rapid evolution of the neutralizing antibody response following HIV infection. Proc. NatL Acad. Sci. USA (2003) 100:4144–1419.
   PubMed Web of Science ®Google Scholar
• WEI X, DECKER JM, WANG S et al: Antibody neutralization and escape by HIV-1.Nature (2003) 422:307–312.
   PubMed Web of Science ®Google Scholar
• BAROUCH BH, KUNSTMAN J, KURODA MJ et al.: Eventual AIDS vaccine failure in rhesus monkey by viral escape from cytotoxic T-lymphocytes. Nature (2002) 415:335–339.
   PubMed Web of Science ®Google Scholar
• BAROUCHDH, LETVIN N: Viral evolution and challenges in the development of HIV vaccines. Vaccine (2002) 4(Suppl.):A66–A68.
   Google Scholar
• BABA TW, LISKA J, KHIMANI AH et al.: Live attenuated, multiply deleted simian immuno-deficiency virus causes AIDS in infants and adult macaques. Nat. Med (1999) 5:194–203.
   PubMed Web of Science ®Google Scholar
• HOFMANN-LEHMANN R, VLASK J, RASMUSSEN RA et al: Post-natal pre and post-exposure passive immunization strategies: protection of neonatal macaques against oral SIV challenge.' Med. PrimatoL (2002) 31:109–119.
   PubMed Web of Science ®Google Scholar
• WYATT R, SODROSKI J: The HIV-1 envelope glycoproteins: fusegens, antigens ans immunogens. Science (1998) 280:1884–1888.
   PubMed Web of Science ®Google Scholar
• KWONG PR, WYATT R, ROBINSON J et al.: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and neutralizing antibody. Nature (1998) 393:648–659.
   PubMed Web of Science ®Google Scholar
• KWONG PD, DOYLES ML, CASPER DJ et al.: HIV-1 evaded antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature (2002) 420:678–682.
   PubMed Web of Science ®Google Scholar
• MCCARTHY M: HIV vaccine fails on Phase III trial. Lancet (2003) 361:775–776.
   Google Scholar
• HONE DM, DEVICO A, FOUTS TR et al.: Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both mucosal and systemic immune compartments. " Hum. Viral. (2002) 5:17–23.
   PubMedGoogle Scholar
• SEDER RA, HILL AVS: Vaccines against intracellular infections requiring cellular immunity. Nature (2000) 406:793–798.
   PubMed Web of Science ®Google Scholar
• KOUP RA, SAFRIT T, CAO Y et al.: Temporal association of cellular immune responses with the initial control of viremia in primary HIV-1 syndrome.j. Virol (1994) 68:4650–4655.
   Web of Science ®Google Scholar
• OGG GS, JINX, BONHOEHER S et al: Quantification of HIV-1 specific cytotoxic T-lymphocytes and plasma viral load and viral DNA. Science (1998) 279:2103–2106.
   PubMed Web of Science ®Google Scholar
• CHERPELIS S, SHRIVASTAVA I, GETTIE A et al.: DNA vaccination with the human immunodeficiency virus type 1 SF162 A V2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection in CD8+ T-cell depleted rhesus macaques. Viral. (2001) 75:1547–1550.
   PubMed Web of Science ®Google Scholar
• LUSSO P: HIV and chemokines: implications for therapy and vaccine. Vaccine (2002) 20:1964–1967.
   PubMed Web of Science ®Google Scholar